In:
Acta Haematologica, S. Karger AG, Vol. 139, No. 1 ( 2018), p. 52-57
Abstract:
〈 b 〉 〈 i 〉 Background: 〈 /i 〉 〈 /b 〉 Surveillance scans performed after autologous stem cell transplant (auto-HCT) for patients with Hodgkin disease (HD) have no proven survival benefit. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 We studied survival differences among patients with HD after auto-HCT whose recurrences were detected on clinical history and exam, versus those detected on routine surveillance scan. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 Among the 98 patients with HD that underwent auto-HCT from 2000 to 2014 at our institution, 30 relapsed, of which 21 were detected radiologically and 9 clinically. There were no statistically significant differences in patient characteristics between the 2 groups. The median time to progression was 118 days for the clinical cohort and 284 days for the radiological cohort ( 〈 i 〉 p 〈 /i 〉 = 0.05). Median overall survival (OS) was 728 days for the clinical cohort, and was not reached for the radiological cohort ( 〈 i 〉 p 〈 /i 〉 = 0.02). 〈 b 〉 〈 i 〉 Discussion: 〈 /i 〉 〈 /b 〉 In our review, most patients with HD after auto-HCT were diagnosed radiologically. Patients whose relapse was diagnosed clinically were likely to be detected earlier and have a shorter OS. Patients with aggressive disease may be detected when clinically relevant, regardless of scanning. Routine scanning may not be necessary in the majority of patients with HD following auto-HCT.
Type of Medium:
Online Resource
ISSN:
0001-5792
,
1421-9662
Language:
English
Publisher:
S. Karger AG
Publication Date:
2018
detail.hit.zdb_id:
1481888-7
detail.hit.zdb_id:
80008-9
Permalink
